Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem disorder in which hepatic metabolic injury coexists with intestinal dysbiosis and neurobehavioral abnormalities. Bile acids function not only as digestive molecules but also as inter-organ signals through the nuclear receptor farnesoid X receptor (FXR) and the membrane receptor Takeda G protein-coupled receptor 5 (TGR5). This review reframes the bile acid–FXR/TGR5 pathway from a brain–gut–liver perspective, with particular emphasis on tissue-specific and sometimes paradoxical receptor functions. We summarize hepatic, intestinal, and central FXR/TGR5 signaling; discuss humoral and vagal routes linking the gut–liver axis with the brain; and critically examine conflicting findings arising from model selection, sex, bile acid profiling strategies, and global vs. tissue-specific receptor manipulation. We further reinterpret current therapeutic approaches, including FXR agonists, TGR5 agonists, GLP-1 receptor agonists, and natural products, in terms of tissue selectivity and central exposure. The available evidence supports a shift from indiscriminate receptor activation toward compartment-selective modulation, while also highlighting the need for prospective human studies, multi-tissue omics, and direct assessment of central bile acid signaling.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: